Neurocrine Biosciences Falls on Corticotropin Data (NBIX)

Neurocrine Biosciences Falls on Corticotropin Data (NBIX) Shares of Neurocrine Biosciences, Inc. NBIX are falling in the after-hours by over 7.00%, currently trading at $5.80. The stock closed Tuesdayssion at $6.25. The company issued a press release that sayd its trial on Corticotropin did not meet its primary endpoint. The company said that the study did not demonstrate a treatment effect compared to placebo. This was a Phase II clinical trial. Neurocrine Biosciences, Inc., incorporated in January 1992, is engaged in developing, discovering and commercializing drugs for the treatment of neurological and endocrine-related diseases and disorders. During the year ended December 31, 2009, the company had eight programs in various stages of research and development, including five programs in clinical development.